Document:

Exhibit 10.1

                                TASTY FRIES, INC.
                             SUBSCRIPTION AGREEMENT

      SUBSCRIPTION AGREEMENT ("Subscription Agreement") made as of this 13th day
of April 2005 between  Tasty  Fries,  Inc.,  a Nevada  corporation  with offices
located at 650 Sentry  Parkway,  Suite One, Blue Bell,  Pennsylvania  19422 (the
"Company"), and the undersigned (the "Subscriber").

      WHEREAS,  pursuant  to  Section  4(2) of the  Securities  Act of 1933,  as
amended (the "Securities Act"), and Rule 506 promulgated thereunder, the Company
desires to sell and the  Subscriber  desires to purchase  250,000  shares of the
Company's  Series A Preferred Stock in a private  placement (the  "Offering") on
the terms and conditions set forth herein;

      NOW,  THEREFORE,  for and in  consideration of the premises and the mutual
covenants hereinafter set forth, the parties hereto do hereby agree as follows:

      I.  SUBSCRIPTION  FOR  SECURITIES;  REPRESENTATIONS  BY AND  COVENANTS  OF
SUBSCRIBER

            1.1 Subscription for Securities. Subject to the terms and conditions
hereinafter  set  forth,  the  Subscriber  hereby  subscribes  for and agrees to
purchase from the Company  250,000  shares of the  Company's  Series A Preferred
Stock ("Shares"),  at a purchase price of $1.00 per share and the Company agrees
to sell such Shares to the Subscriber for said purchase price.

            1.2 Reliance on  Exemptions.  The Subscriber  acknowledges  that the
Offering  has not been  reviewed by the United  States  Securities  and Exchange
Commission  (the  "SEC") or any state  agency  because  it is  intended  to be a
nonpublic  offering exempt from the registration  requirements of the Securities
Act and state  securities  laws. The Subscriber  understands that the Company is
relying in part upon the truth and accuracy of, and the Subscriber's  compliance
with  the   representations,   warranties,   agreements,   acknowledgments   and
understandings  of the  Subscriber  set forth herein in order to  determine  the
availability of such exemptions and the eligibility of the Subscriber to acquire
the Shares.

            1.3 Investment  Purpose.  The Subscriber  represents that the Shares
are being  purchased for its own account,  for investment  purposes only and not
for  distribution  or  resale to others  in  contravention  of the  registration
requirements of the Securities Act. The Subscriber  agrees that it will not sell
or otherwise transfer the Shares unless they are registered under the Securities
Act or unless an exemption from such registration is available.

            1.4 Accredited Investor. The Subscriber represents and warrants that
it is an "accredited investor" as such term is defined in Rule 501 of Regulation
D promulgated under the Securities Act, and that it is able to bear the economic
risk of any investment in the Shares.

<PAGE>

            1.5 Risk of Investment.  The Subscriber recognizes that the purchase
of the Shares  involves a high degree of risk in that:  (a) an investment in the
Company  is highly  speculative  and only  investors  who can afford the loss of
their entire investment should consider investing in the Company and the Shares;
(b)  transferability  of the Shares is limited;  and (c) the Company may require
substantial  additional  funds to operate its  business  and  subsequent  equity
financings will dilute the ownership and voting interests of Subscriber.

            1.6 Prior Investment Experience. The Subscriber acknowledges that it
has prior  investment  experience and that it recognizes the highly  speculative
nature of this investment.

            1.7 Information.  The Subscriber acknowledges careful review of this
Subscription  Agreement as well as the Company's filings with the Securities and
Exchange Commission,  as required pursuant to the Securities and Exchange Act of
1934, and specifically the Company's  current reports on Form 8-K filed with the
Securities  and Exchange  Commission on March 23, 2005,  April 1, 2005 and April
13, 2005, which are available on the Internet at www.sec.gov (collectively,  the
"Offering  Documents"),  all of which  the  undersigned  acknowledges  have been
provided to the  undersigned.  The undersigned has been given the opportunity to
ask questions of, and receive answers from, the Company concerning the terms and
conditions  of this  Offering  and the  Offering  Documents  and to obtain  such
additional information,  to the extent the Company possesses such information or
can acquire it without  unreasonable effort or expense,  necessary to verify the
accuracy of same as the undersigned  reasonably desires in order to evaluate the
investment.   The  undersigned  understands  the  Offering  Documents,  and  the
undersigned  has had the  opportunity to discuss any questions  regarding any of
the Offering  Documents with its counsel or other advisor.  Notwithstanding  the
foregoing,  the only  information  upon which the undersigned has relied is that
set  forth  in  the  Offering   Documents.   The  undersigned  has  received  no
representations  or  warranties  from the  Company,  its  employees,  agents  or
attorneys  in making  this  investment  decision  other than as set forth in the
Offering  Documents.  The  undersigned  does not desire to receive  any  further
information.

            1.8 No  Representations.  The  Subscriber  hereby  represents  that,
except as expressly set forth in the Offering  Documents,  no representations or
warranties  have  been  made to the  Subscriber  by the  Company  or any  agent,
employee or affiliate of the Company,  and in entering into this transaction the
Subscriber is not relying on any  information  other than that  contained in the
Offering  Documents  and  the  results  of  independent   investigation  by  the
Subscriber.

            1.9 Tax Consequences.  The Subscriber acknowledges that the Offering
may involve tax consequences and that the contents of the Offering  Documents do
not contain tax advice or information.  The Subscriber acknowledges that it must
retain its own professional  advisors to evaluate the tax and other consequences
of an investment in the Shares.

            1.10  Transfer  or Resale.  The  Subscriber  understands  and hereby
acknowledges  that the Company is under no  obligation  to  register  the Shares
under the Securities  Act except as contained  herein.  The Subscriber  consents
that the Company  may, if it desires,  permit the  transfer of the Shares out of
the  Subscriber's  name only  when the  Subscriber's  request  for  transfer  is
accompanied by an opinion of counsel reasonably satisfactory to the Company that
neither  the  sale nor the  proposed  transfer  results  in a  violation  of the
Securities Act or any applicable state "blue sky" laws.

                                       2
<PAGE>

            1.11  Legends.  The  Subscriber  understands  that the  certificates
representing the Shares,  until such time as they have been registered under the
Securities Act, shall bear a restrictive  legend in substantially  the following
form  (and a  stop-transfer  order  may  be  placed  against  transfer  of  such
certificates or other instruments):

            THE  SECURITIES  REPRESENTED  BY  THIS  CERTIFICATE  HAVE  NOT  BEEN
            REGISTERED  UNDER  THE  SECURITIES  ACT  OF  1933,  AS  AMENDED,  OR
            APPLICABLE  STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
            FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN
            EFFECTIVE  REGISTRATION  STATEMENT  FOR  THE  SECURITIES  UNDER  THE
            SECURITIES ACT OF 1933, AS AMENDED,  OR APPLICABLE  STATE SECURITIES
            LAWS, OR (B) AN OPINION OF COUNSEL, IN A REASONABLY ACCEPTABLE FORM,
            THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
            SECURITIES LAWS, OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID
            ACT.

            The legend set forth above  shall be removed  and the Company  shall
issue a  certificate  without such legend to the holder of the Shares upon which
it is stamped,  if (a) such Securities are being sold pursuant to a registration
statement  under the Securities  Act, (b) such holder delivers to the Company an
opinion of counsel,  in a  reasonably  acceptable  form,  to the Company  that a
disposition  of the  Shares is being made  pursuant  to an  exemption  from such
registration,  or (c) such holder provides the Company with reasonable assurance
that a disposition  of the Securities may be made pursuant to the Rule 144 under
the  Securities  Act  without  any  restriction  as to the number of  securities
acquired as of a particular date that can then be immediately sold.

            1.12 No General  Solicitation.  The Subscriber  represents  that the
Subscriber  was not  induced  to invest by any form of general  solicitation  or
general  advertising  including,  but not  limited  to, the  following:  (a) any
advertisement,   article,   notice  or  other  communication  published  in  any
newspaper,  magazine or similar media or broadcast  over the news or radio;  and
(b)  any  seminar  or  meeting  whose  attendees  were  invited  by any  general
solicitation or advertising.

            1.13  Validity;  Enforcement.  If the  Subscriber is a  corporation,
partnership, trust or other entity, the Subscriber represents and warrants that:
(a) it is  authorized  and  otherwise  duly  qualified  to purchase and hold the
Shares;  and (b) that this  Subscription  Agreement  has been  duly and  validly
authorized,  executed  and  delivered  and  constitutes  the legal,  binding and
enforceable  obligation of the undersigned.  If the Subscriber is an individual,
the Subscriber represents and warrants that this Subscription Agreement has been
duly and validly  executed and delivered and constitutes the legal,  binding and
enforceable obligation of the undersigned.

                                       3
<PAGE>

            1.14 Address.  The Subscriber  hereby represents that the address of
the  Subscriber  furnished  by the  Subscriber  at the end of this  Subscription
Agreement  is the  undersigned's  principal  residence if the  Subscriber  is an
individual or its  principal  business  address if it is a corporation  or other
entity.

            1.15 Foreign  Subscriber.  If the  Subscriber is not a United States
person, such Subscriber hereby represents that it has satisfied itself as to the
full  observance  of the  laws  of  its  jurisdiction  in  connection  with  any
invitation  to  subscribe  for  the  Shares  or  any  use of  this  Subscription
Agreement, including: (a) the legal requirements within its jurisdiction for the
purchase of the Shares; (b) any foreign exchange restrictions applicable to such
purchase;  (c) any  governmental or other consents that may need to be obtained;
and (d) the income tax and other tax consequences,  if any, that may be relevant
to the  purchase,  holding,  redemption,  sale or transfer  of the Shares.  Such
Subscriber's   subscription  and  payment  for,  and  its  continued  beneficial
ownership of the Shares,  will not violate any  applicable  securities  or other
laws of the Subscriber's jurisdiction.

      II. REGISTRATION RIGHTS

            2.1 The Company  agrees that if, at any time, and from time to time,
after the date hereof the Board of Directors of the Company (the "Board")  shall
authorize the filing of a registration statement under the Securities Act (other
than a registration  statement on Form S-8, Form S-4 or any other form that does
not include  substantially  the same  information as would be required in a form
for the general  registration  of  securities)  in connection  with the proposed
offer of any of its  securities  by it or any of its  stockholders,  the Company
shall: (A) promptly notify the Subscriber that such registration  statement will
be filed  and that the  shares  of  common  stock  underlying  the  Shares  (the
"Registrable  Securities")  then held by the Subscriber will be included in such
registration  statement;  (B) cause such registration  statement to cover all of
such Registrable  Securities  issued to the Subscriber;  (C) use best efforts to
cause such  registration  statement to become  effective as soon as practicable;
and (D) take all other  reasonable  action  necessary under any federal or state
law or regulation of any  governmental  authority to permit all such Registrable
Securities that have been issued to such holder to be sold or otherwise disposed
of, and will maintain such  compliance  with each such federal and state law and
regulation  of any  governmental  authority  for the period  necessary  for such
holder  to   promptly   effect   the   proposed   sale  or  other   disposition.
Notwithstanding  any other provision of this Section 2.1, the Company may at any
time, abandon or delay any registration  commenced by the Company.  In the event
of such an  abandonment  by the  Company,  the Company  shall not be required to
continue registration of the Registrable Securities, the Holder shall retain the
right to request inclusion of shares as set forth above.

      III. MISCELLANEOUS

            3.1 Notice. Any notices,  consents,  waivers or other communications
required or permitted to be given under the terms of this Subscription Agreement
must be in writing and will be deemed to have been delivered:  (a) upon receipt,
when delivered  personally,  (b) upon receipt,  when sent by facsimile (provided
confirmation of transmission  is  mechanically or  electronically  generated and
kept on file by the sending  party),  or (c) one (1) business day after  deposit
with an overnight courier service,  in each case properly addressed to the party
to receive the same. The addresses and facsimile numbers for such communications
shall be:

                                       4
<PAGE>

            If to the Company:

            650 Sentry Parkway, Suite One
            Blue Bell, Pennsylvania 19422
            Attn: Edward C. Kelly
            Telephone: (610) 941-2109
            Facsimile:

            If to the Subscriber,  to its address and facsimile number set forth
at the end of this  Subscription  Agreement,  or to such  other  address  and/or
facsimile  number  and/or to the  attention of such other person as specified by
written notice given to the Company five (5) days prior to the  effectiveness of
such change.  Written confirmation of receipt (a) given by the recipient of such
notice,   consent,   waiver  or  other   communication,   (b)   mechanically  or
electronically  generated by the sender's facsimile machine containing the time,
date,  recipient  facsimile  number  and an  image  of the  first  page  of such
transmission,  or  (c)  provided  by  an  overnight  courier  service  shall  be
rebuttable evidence of personal service, receipt by facsimile or receipt from an
overnight  courier  service in  accordance  with clause  (a),  (b) or (c) above,
respectively.

            3.2  Entire  Agreement;   Amendment.   This  Subscription  Agreement
supersedes all other prior oral or written  agreements  between the  Subscriber,
the Company, their affiliates and persons acting on their behalf with respect to
the  matters  discussed  herein,   and  this  Subscription   Agreement  and  the
instruments  referenced  herein contain the entire  understanding of the parties
with  respect  to  the  matters  covered  herein  and  therein  and,  except  as
specifically set forth herein or therein, neither the Company nor the Subscriber
makes any representation, warranty, covenant or undertaking with respect to such
matters.  No provision of this  Subscription  Agreement may be amended or waived
other than by an instrument in writing  signed by the Company and the holders of
at  least  a  majority  of the  Shares  then  outstanding  (determined  on an as
exercised to common stock  basis) (or if prior to the closing,  the  Subscribers
purchasing at least a majority of the Shares to be purchased at the closing). No
such amendment shall be effective to the extent that it applies to less than all
of the holders of the Shares then outstanding.

            3.3 Severability.  If any provision of this  Subscription  Agreement
shall be  invalid or  unenforceable  in any  jurisdiction,  such  invalidity  or
unenforceability  shall  not  affect  the  validity  or  enforceability  of  the
remainder of this Subscription Agreement in that jurisdiction or the validity or
enforceability  of any  provision  of this  Subscription  Agreement in any other
jurisdiction.

            3.4 Governing Law; Jurisdiction; Waiver of Jury Trial. All questions
concerning the construction,  validity,  enforcement and  interpretation of this
Subscription  Agreement  shall be governed by the internal  laws of the State of
Pennsylvania,  without  giving  effect to any choice of law or  conflict  of law
provision  or  rule  (whether  of  the  State  of   Pennsylvania  or  any  other
jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of Pennsylvania.  Each party hereby irrevocably  submits to
the  non-exclusive  jurisdiction  of the state and  federal  courts  sitting  in
Pennsylvania  for the  adjudication  of any dispute  hereunder or in  connection
herewith or with any transaction  contemplated  hereby or discussed herein,  and
hereby  irrevocably  waives,  and  agrees  not to assert in any suit,  action or
proceeding,  any claim that it is not personally  subject to the jurisdiction of
any  such  court,  that  such  suit,  action  or  proceeding  is  brought  in an
inconvenient  forum or that the  venue of such  suit,  action or  proceeding  is
improper.  Each party hereby  irrevocably waives personal service of process and
consents  to process  being  served in any such suit,  action or  proceeding  by
mailing a copy thereof to such party at the address for such notices to it under
this  Subscription  Agreement and agrees that such service shall constitute good
and sufficient  service of process and notice thereof.  Nothing contained herein
shall be  deemed to limit in any way any right to serve  process  in any  manner
permitted by law.  Each party hereby  irrevocably  waives any right it may have,
and agrees not to  request,  a jury trial for the  adjudication  of any  dispute
hereunder or in connection with or arising out of this Subscription Agreement or
any transaction contemplated hereby.

                                       5
<PAGE>

            3.5 Headings.  The headings of this  Subscription  Agreement are for
convenience   of   reference   and  shall  not  form  part  of,  or  affect  the
interpretation of, this Subscription Agreement.

            3.6 Successors And Assigns.  This  Subscription  Agreement  shall be
binding  upon and inure to the  benefit  of the  parties  and  their  respective
successors and assigns. The Company shall not assign this Subscription Agreement
or any rights or obligations  hereunder without the prior written consent of the
holders of at least a majority the Shares then outstanding,  except by merger or
consolidation.  The Subscriber shall not assign its rights hereunder without the
consent of the Company, which consent shall not be unreasonably withheld.

            3.7 No Third Party  Beneficiaries.  This  Subscription  Agreement is
intended for the benefit of the parties  hereto and their  respective  permitted
successors  and  assigns,  and is not for the benefit of, nor may any  provision
hereof be enforced by, any other person.

            3.8 Survival.  The  representations and warranties of the Subscriber
contained  in  Article I and the  agreements  set forth this  Article  III shall
survive closing for a period of two years.

            3.9 Further Assurances. Each party shall do and perform, or cause to
be done and performed,  all such further acts and things,  and shall execute and
deliver all such other agreements,  certificates,  instruments and documents, as
the other  party may  reasonably  request  in order to carry out the  intent and
accomplish the purposes of this  Subscription  Agreement and the consummation of
the transactions contemplated hereby.

            3.10 No Strict Construction.  The language used in this Subscription
Agreement  will be deemed to be the  language  chosen by the  parties to express
their mutual intent, and no rules of strict construction will be applied against
any party.

                                       6
<PAGE>

            3.11 Legal Representation.  The Subscriber acknowledges that: (a) it
has read  this  Subscription  Agreement;  and (b) it  understands  the terms and
consequences of this Subscription  Agreement and is fully aware of its legal and
binding effect.

            3.12  Counterparts.  This Subscription  Agreement may be executed in
two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when  counterparts have been signed by
each party and delivered to the other party; provided that a facsimile signature
shall be  considered  due  execution  and shall be  binding  upon the  signatory
thereto with the same force and effect as if the signature were an original, not
a facsimile signature.

                            [Signature page follows.]

                                       7
<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Subscription  Agreement
as of the day and year first written above.

Eric Whetstone                          No. of Shares: 250,000
-------------------------                             --------------------------
Name of Subscriber

/s/ ERIC WHETSTONE
-----------------------------------
Signature

Eric Whetstone
Name (Please Print)

-----------------------------------
Title

-----------------------------------

-----------------------------------

-----------------------------------
Address of Subscriber

-----------------------------------
Taxpayer Identification
Number of Subscriber

                                        Subscription Accepted:

                                        TASTY FRIES, INC.

                                        By: /s/ EDWARD C. KELLY
                                            ------------------------------------
                                        Name:  Edward C. Kelly
                                        Title: Chief Executive Officer

                                       8EXHIBIT 4.1

                         COMMON STOCK PURCHASE AGREEMENT

THIS COMMON STOCK PURCHASE AGREEMENT ("Agreement") is made and entered into as
of April 6, 2005 (the "Effective Date"), by and between GERON CORPORATION, a
Delaware corporation having its principal place of business at 230 Constitution
Drive, Menlo Park, California 94025 ("Geron"), and TRANSGENOMIC, INC., a
Delaware corporation having its principal place of business at 12325 Emmet
Street, Omaha, Nebraska 68164 ("Transgenomic").

     A.   Geron and Transgenomic are the parties to that certain Supply
          Agreement dated as of June 15, 2002 (the "Supply Agreement"), and
          related Addendum Agreements ("Addendum Agreement") under which Geron
          has agreed to purchase certain products from Transgenomic and
          Transgenomic has agreed to supply such products to Geron on the terms
          set forth therein.

     B.   Pursuant to Addendum Agreement No. 9, dated as of April 6, 2005, Geron
          may pay the purchase price of products by delivery of shares of
          Geron's Common Stock (the "Shares").

THE PARTIES AGREE AS FOLLOWS:

    1. ISSUANCE OF SHARES; ADJUSTMENTS.

           1.1    As payment of the First Installment specified in Addendum
                  Agreement No. 9, Geron will issue and deliver certificates for
                  76,005 Shares. Upon issuance and delivery of the
                  certificate(s) for the Shares, all Shares shall be duly
                  authorized and validly issued and represent fully paid shares
                  of Geron's Common Stock.

    2. CLOSING; DELIVERY.

           2.1    The consummation of the transaction contemplated by this
                  Agreement (a "Closing") shall be held at such time and place
                  as is mutually agreed upon between the parties, but in any
                  event no later April 13, 2005 (the "Closing Date"). At the
                  Closing, Geron shall deliver to Transgenomic one or more
                  certificates representing all of the Shares, which Shares
                  shall be issued in the name of Transgenomic or its designee
                  and in such denominations as Transgenomic shall specify.

           2.2    Geron's obligations to issue and deliver the stock
                  certificate(s) representing the Shares to Transgenomic at the
                  Closing shall be subject to the following conditions, which
                  may be waived by Geron:

                  2.2.1  the covenants and obligations that Transgenomic is
                         required to perform or to comply with pursuant to this
                         Agreement, at or prior to the Closing, must have been
                         duly performed and complied with in all material
                         respects; and

                  2.2.2  the representations and warranties made by Transgenomic
                         herein shall be true and correct in all material
                         respects as of the Closing Date.

           2.3    Transgenomic's obligation to accept delivery of the stock
                  certificate(s) representing the Shares at the Closing shall be
                  subject to the following conditions, any one or more of which
                  may be waived by Transgenomic:

                  2.3.1  the covenants and obligations that Geron is required to
                         perform or to comply with pursuant to this Agreement,
                         at or prior to the Closing, must have been duly
                         performed and complied with in all material respects;

                                       1

<PAGE>

                  2.3.2  Geron shall have available under its Certificate of
                         Incorporation sufficient authorized shares of Common
                         Stock to issue the Shares to Transgenomic; and

                  2.3.3  the representation and warranties made by the Geron
                         herein shall be true and correct in all material
                         respects as of any Closing Date.

    3. RESTRICTIONS ON RESALE OF SHARES.

           3.1    Legends. Transgenomic understands and acknowledges that the
                  Shares are not registered under the Securities Act of 1933
                  (the "Act"), and that under the Act and other applicable laws
                  Transgenomic may be required to hold such Shares for an
                  indefinite period of time. Each stock certificate representing
                  Shares shall bear the following legends:

                  "THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
                  UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). ANY
                  TRANSFER OF SUCH SECURITIES SHALL BE INVALID UNLESS A
                  REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH
                  TRANSFER OR, IN THE OPINION OF COUNSEL REASONABLY ACCEPTABLE
                  TO GERON, SUCH REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER
                  TO COMPLY WITH THE ACT. THE SECURITIES REPRESENTED HEREBY ARE
                  SUBJECT TO THE TERMS OF THE COMMON STOCK PURCHASE AGREEMENT,
                  DATED AS OF APRIL 6, 2005. A COPY OF THE AGREEMENT CAN BE
                  OBTAINED FROM THE SECRETARY OF GERON."

           3.2    Limits on Sales. Transgenomic agrees that if it decides to
                  resell some or all of the Shares, it will do so only in an
                  appropriate manner based upon whether the shares are
                  registered or unregistered, i.e., on the Nasdaq National
                  Market or in a Rule 144A compliant transaction. Subject to the
                  foregoing restrictions, Transgenomic may sell or resell the
                  Shares in any lot size, or at any volume, desired by
                  Transgenomic.

    4. REGISTRATION RIGHTS

           4.1    Geron agrees to make commercially reasonable best efforts to
                  file with the Securities and Exchange Commission (the
                  "Commission") within five (5) business days after the Closing
                  Date, a registration statement under the Act (the
                  "Registration Statement"), on Form S-3 or other appropriate
                  form, so as to permit a non-underwritten public offering and
                  resale of the Shares under the Act by Transgenomic. Geron
                  agrees to diligently pursue making the Registration Statement
                  effective. Geron will notify Transgenomic of the effectiveness
                  of the Registration Statement within one (1) business day of
                  receiving notice from the Commission.

           4.2    Geron will maintain the Registration Statement and any
                  post-effective amendment thereto filed under this Section 4
                  effective under the Act until the earliest of (i) the date
                  that none of the Shares covered by such Registration Statement
                  are issued and outstanding, (ii) the date that all of the
                  Shares have been sold pursuant to such Registration Statement,
                  (iii) the date Transgenomic receives an opinion of counsel to
                  Geron, which counsel shall be reasonably acceptable to
                  Transgenomic, that the Shares may be sold under the provisions
                  of Rule 144 without limitation as to volume, (iv) the date
                  that all Shares have been otherwise transferred to persons who
                  may trade such shares without restriction under the Act, and
                  Geron has delivered a new certificate or other evidence of
                  ownership for such securities not bearing a restrictive
                  legend, or (v) the date all Shares may be sold at any time,
                  without volume or manner of sale limitations pursuant to Rule
                  144(k) or any similar provision then in effect under the Act
                  in the opinion of counsel to Geron, which counsel shall be
                  reasonably acceptable to Transgenomic.

                                       2

<PAGE>

           4.3    Geron, at its expense, shall furnish to Transgenomic with
                  respect to the Shares registered under the Registration
                  Statement such reasonable number of copies of the Registration
                  Statement, prospectuses and preliminary prospectuses in
                  conformity with the requirements of the Act and such other
                  documents as Transgenomic may reasonably request, in order to
                  facilitate the public sale or other disposition of all or any
                  of the Shares by Transgenomic, provided, however, that the
                  obligation of Geron to deliver copies of prospectuses or
                  preliminary prospectuses to Transgenomic shall be subject to
                  the receipt by Geron of reasonable assurances from
                  Transgenomic that Transgenomic will comply with the applicable
                  provisions of the Act and of such other securities or blue sky
                  laws as may be applicable in connection with any use of such
                  prospectuses or preliminary prospectuses.

           4.4    All fees, disbursements and out-of-pocket expenses and costs
                  incurred by Geron in connection with the preparation and
                  filing of the Registration Statement under Section 4.1 and in
                  complying with applicable securities and Blue Sky laws
                  (including, without limitation, all attorneys' fees of Geron)
                  shall be borne by Geron. Transgenomic shall bear the cost of
                  fees and expenses of Transgenomic's counsel.

           4.5    Geron will advise Transgenomic promptly after it shall receive
                  notice or obtain knowledge of the issuance of any stop order
                  by the Commission delaying or suspending the effectiveness of
                  the Registration Statement or of the initiation of any
                  proceeding for that purpose, and Geron will use its
                  commercially reasonable efforts to prevent the issuance of any
                  stop order or to obtain its withdrawal at the earliest
                  possible moment if such stop order should be issued.

           4.6    With a view to making available to Transgenomic the benefits
                  of Rule 144 (or its successor rule) and any other rule or
                  regulation of the Commission that may at the time permit
                  Transgenomic to sell the Shares to the public without
                  registration, Geron covenants and agrees to: (i) make and keep
                  public information available, as those terms are understood
                  and defined in Rule 144, until the earliest of (A) such date
                  as all of the Shares may be resold pursuant to Rule 144(k) or
                  any other rule of similar effect or (B) such date as all of
                  the Shares shall have been resold; and (ii) file with the
                  Commission in a timely manner all reports and other documents
                  required of Geron under the Act and under the Exchange Act of
                  1934, as amended.

           4.7    Transgenomic will cooperate with Geron in all respects in
                  connection with this Agreement, including timely supplying all
                  information reasonably requested by Geron (which shall include
                  all information regarding Transgenomic and proposed manner of
                  sale of the Shares required to be disclosed in any
                  Registration Statement) and executing and returning all
                  documents reasonably requested in connection with the
                  registration and sale of the Shares and entering into and
                  performing their obligations under any underwriting agreement,
                  if the offering is an underwritten offering, in usual and
                  customary form, with the managing underwriter or underwriters
                  of such underwritten offering. Nothing in this Agreement shall
                  obligate Transgenomic to consent to be named as an underwriter
                  in any Registration Statement.

    5. INDEMNIFICATION.

           5.1    Geron agrees to indemnify and hold harmless Transgenomic (and
                  each person, if any, who controls Transgenomic within the
                  meaning of Section 15 of the Act, and each officer and
                  director of Transgenomic) against any and all losses, claims,
                  damages or liabilities (or actions or proceedings in respect
                  thereof), joint or several, directly or indirectly based upon
                  or arising out of (i) any untrue statement or alleged untrue
                  statement of any material fact contained in the Registration
                  Statement, any preliminary prospectus, final prospectus or
                  summary prospectus contained therein or used in connection
                  with the offering of the Shares, or any amendment or
                  supplement thereto, or (ii) any omission or alleged omission

                                       3

<PAGE>

                  to state a material fact required to be stated therein or
                  necessary to make the statements therein not misleading; and
                  Geron will reimburse each such indemnified party for any legal
                  or any other expenses reasonably incurred by them in
                  connection with investigating, preparing, pursuing or
                  defending any such loss, claim, damage, liability, action or
                  proceeding, except insofar as any such loss, claim, damage,
                  liability, action, proceeding or expense (A) arises out of or
                  is based upon an untrue statement or alleged untrue statement
                  or omission or alleged omission made in the Registration
                  Statement, any such preliminary prospectus, final prospectus,
                  summary prospectus, amendment or supplement in reliance upon
                  and in conformity with written information furnished to Geron
                  by Transgenomic or such other person expressly for use in the
                  preparation thereof, (B) the failure of Transgenomic to comply
                  with its covenants and agreements contained in Sections 7.1 or
                  7.5.2 hereof or (C) any misstatement or omission in any
                  prospectus that is corrected in any subsequent prospectus that
                  was delivered to Transgenomic prior to the pertinent sale or
                  sales by Transgenomic. Such indemnity shall remain in full
                  force and effect, regardless of any investigation made by such
                  indemnified party and shall survive the transfer of the Shares
                  by Transgenomic.

           5.2    Transgenomic agrees to indemnify and hold harmless Geron (and
                  each person, if any, who controls Geron within the meaning of
                  Section 15 of the Act, each officer of Geron who signs the
                  Registration Statement and each director of Geron) from and
                  against losses, claims, damages or liabilities (or actions or
                  proceedings in respect thereof), joint or several, directly or
                  indirectly based upon or arising out of, (i) any failure of
                  Transgenomic to comply with the covenants and agreements
                  contained in Sections 7.1 and 7.5.2 hereof or (ii) any untrue
                  statement of a material fact contained in the Registration
                  Statement or any omission of a material fact required to be
                  stated in the Registration Statement or necessary in order to
                  make the statements in the Registration Statement not
                  misleading if such untrue statement or omission was made in
                  reliance upon and in conformity with written information
                  furnished to Geron by on behalf of Transgenomic specifically
                  for use in preparation of the Registration Statement;
                  provided, however, that Transgenomic shall not be liable in
                  any such case for (A) any untrue statement or omission in the
                  Registration Statement, prospectus, or other such document
                  which statement is corrected by Transgenomic and delivered to
                  Geron prior to the sale from which such loss occurred, (B) any
                  untrue statement or omission in any prospectus which is
                  corrected by Transgenomic in any subsequent prospectus, or
                  supplement or amendment thereto, and delivered to Geron prior
                  to the sale or sales from which a loss or liability arose, or
                  (C) any failure by Geron to fulfill any of its obligations
                  under Section 5.1 hereof.

           5.3    Promptly after receipt by any indemnified person of a notice
                  of a claim or the beginning of any action in respect of which
                  indemnity is to be sought against an indemnifying person
                  pursuant to this Section 5, such indemnified person shall
                  notify the indemnifying person in writing of such claim or of
                  the commencement of such action, but the omission to so notify
                  the indemnifying party will not relieve it from any liability
                  which it may have to any indemnified party under this Section
                  5 (except to the extent that such omission materially and
                  adversely affects the indemnifying party's ability to define
                  such action) or from any liability otherwise than under this
                  Section 5. Subject to the provisions hereinafter stated, in
                  case any such action shall be brought against an indemnified
                  person, the indemnifying person shall be entitled to
                  participate therein, and, to the extent that it shall elect by
                  written notice delivered to the indemnified party promptly
                  after receiving the aforesaid notice from such indemnified
                  party, shall be entitled to assume the defense thereof, with
                  counsel reasonably satisfactory to such indemnified person.
                  After notice from the indemnifying person to such indemnified
                  person of its election to assume the defense thereof, such
                  indemnifying person shall not be liable to such indemnified
                  person for any legal expense subsequently incurred by such
                  indemnified person in connection with the defense thereof,
                  provided, however, that if there exists or shall exist a
                  conflict of interest that would make inappropriate, in the
                  reasonable opinion of counsel to the indemnified person, for

                                       4

<PAGE>

                  the same counsel to represent both the indemnified person and
                  such indemnifying person or any affiliate or associate
                  thereof, the indemnified person shall be entitled to retain
                  its own counsel at the expense of such indemnifying person;
                  provided, however, that no indemnifying person shall be
                  responsible for the fees and expenses of more than on separate
                  counsel (together with appropriate local counsel) for all
                  indemnified parties. In no event shall any indemnifying person
                  be liable in respect to any amounts paid in settlement of any
                  action unless the indemnifying person shall have approved the
                  terms of such settlement. No indemnifying person shall,
                  without the prior written consent of the indemnified person,
                  effect any settlement of any pending or threatened proceeding
                  in respect of which any indemnified person is or could have
                  been a party and indemnification could have been sought
                  hereunder by such indemnified person, unless such settlement
                  includes an unconditional release of such indemnified person
                  from all liability on claims that are the subject matter of
                  such proceeding.

           5.4    The provisions of this Section 5 shall survive the termination
                  of this Agreement.

    6. REPRESENTATIONS AND ACKNOWLEDGEMENT OF GERON.

       Geron hereby represents, warrants and covenants to Transgenomic as
       follow:

           6.1    Organization, Good Standing and Qualification. Geron is a
                  corporation duly organized, validly existing and in good
                  standing under the laws of the State of Delaware and has all
                  requisite corporate power and authority to carry on its
                  business as now conducted and as presently proposed to be
                  conducted. Geron is duly qualified to transact business and is
                  in good standing as a foreign corporation in each jurisdiction
                  in which the failure to so qualify would have a material
                  adverse effect on its business or properties.

           6.2    Authorization. All corporate action on the party of Company,
                  its officers, directors and stockholders necessary for the
                  authorization, execution and delivery of this Agreement, the
                  performance of all obligations of Company hereunder and the
                  authorization, issuance and delivery of the Shares has been
                  taken or will be taken prior to the Closing, and this
                  Agreement, when executed and delivered will constitute valid
                  and legally binding obligations of Geron, enforceable against
                  Geron in accordance with their terms, except as limited by
                  applicable bankruptcy, insolvency, reorganization, moratorium,
                  fraudulent conveyance and other laws of general application
                  affecting enforcement of creditors' rights generally, as
                  limited by laws relating to the availability of specific
                  performance, injunctive relief or other equitable remedies.

           6.3    Valid Issuance of Common Stock. The Shares, when issued, sold
                  and delivered in accordance with the terms hereof for the
                  consideration expressed herein, will be duly and validly
                  authorized and issued, fully paid and nonassessable and free
                  of restrictions on transfer other than restrictions on
                  transfer under this Agreement and applicable state and federal
                  securities laws.

           6.4    Legal Proceedings and Orders. There is no action, suit,
                  proceeding or investigation pending or threatened against
                  Geron that questions the validity of this Agreement or the
                  right of Geron to enter into this Agreement or to consummate
                  this transactions contemplated hereby, nor is Geron aware of
                  any basis for any of the forgoing. Geron is neither a party
                  nor subject to the provisions of any order, writ, injunction,
                  judgment or decree of any court or government agency or
                  instrumentality that would affect the ability of Geron to
                  enter into this Agreement or to consummate the transactions
                  contemplated hereby.

    7. REPRESENTATIONS AND ACKNOWLEDGMENTS OF TRANSGENOMIC.

       Transgenomic hereby represents, warrants, acknowledges and agrees that:

                                       5

<PAGE>

           7.1    Investment. Transgenomic is acquiring the Shares for
                  Transgenomic's own account, and not directly or indirectly for
                  the account of any other person. Transgenomic is acquiring the
                  Shares for investment and not with a view to distribution or
                  resale thereof, except in compliance with the Act and any
                  applicable state law regulating securities.

           7.2    Access to Information. Transgenomic has consulted with its own
                  attorney, accountant, or investment advisor as Transgenomic
                  has deemed advisable with respect to the investment and has
                  determined its suitability for Transgenomic. Transgenomic has
                  had the opportunity to ask questions of, and to receive
                  answers from, appropriate executive officers of Geron with
                  respect to the terms and conditions of the transactions
                  contemplated hereby and with respect to the business, affairs,
                  financial condition and results of operations of Geron.
                  Transgenomic has had access to such financial and other
                  information as is necessary in order for Transgenomic to make
                  a fully informed decision as to investment in Geron, and has
                  had the opportunity to obtain any additional information
                  necessary to verify any of such information to which
                  Transgenomic has had access. Transgenomic acknowledges that
                  neither Geron nor any of its officers, directors, employees,
                  agents, representatives, or advisors have made any
                  representation or warranty other than those specifically
                  expressed herein.

           7.3    Business and Financial Expertise. Transgenomic further
                  represents and warrants that it has such business or financial
                  expertise as to be able to evaluate its investment in Geron
                  and purchase of the Shares.

           7.4    Speculative Investment. Transgenomic acknowledges that the
                  investment in Geron represented by the Shares is highly
                  speculative in nature and is subject to a high degree of risk
                  of loss in whole or in part; the amount of such investment is
                  within Transgenomic's risk capital means and is not so great
                  in relation to Transgenomic's total financial resources as
                  would jeopardize the personal financial needs of Transgenomic
                  in the event such investment were lost in whole or in part.

           7.5    Unregistered Securities.  Transgenomic acknowledges that:

                  7.5.1  Transgenomic must bear the economic risk of investment
                         for an indefinite period of time because the Shares
                         have not been registered under the Act and therefore
                         cannot and will not be sold unless they are
                         subsequently registered under the Act or an exemption
                         from such registration is available. Geron has made no
                         agreements, covenants or undertakings whatsoever to
                         register any of the Shares under the Act, except as
                         provided in Section 4 above. Geron has made no
                         representations, warranties or covenants whatsoever as
                         to whether any exemption from the Act, including,
                         without limitation, any exemption for limited sales in
                         routine brokers' transactions pursuant to Rule 144
                         under the Act, will become available and any such
                         exemption pursuant to Rule 144, if available at all,
                         will not be available unless: (i) a public trading
                         market then exists in Geron's common stock, (ii) Geron
                         has complied with the information requirements of Rule
                         144, and (iii) all other terms and conditions of Rule
                         144 have been satisfied.

                  7.5.2  Transfer of the Shares has not been registered or
                         qualified under any applicable state law regulating
                         securities and, therefore, the Shares cannot and will
                         not be sold unless they are subsequently registered or
                         qualified under any such act or an exemption therefrom
                         is available. Geron has made no agreements, covenants
                         or undertakings whatsoever to register or qualify any
                         of the Shares under any such act. Geron has made no
                         representations, warranties or covenants whatsoever as
                         to whether any exemption from any such act will become
                         available.

                                       6

<PAGE>

                  7.5.3  Transgenomic hereby certifies that it is an "Accredited
                         Investor" as that term is defined in Rule 501 under the
                         Act.

    8.     TAX ADVICE. Transgenomic acknowledges that Transgenomic has not
           relied and will not rely upon Geron or Geron's counsel with respect
           to any tax consequences related to the ownership, purchase, or
           disposition of the Shares. Transgenomic assumes full responsibility
           for all such consequences and for the preparation and filing of all
           tax returns and elections which may or must be filed in connection
           with the Shares.

    9.     NOTICES. Any notice or other communication required or permitted
           hereunder shall be in writing and shall be deemed to have been duly
           given on the date of delivery if delivered personally or by
           facsimile, or one day, not including Saturdays, Sundays, or national
           holidays, after sending if sent by national overnight delivery
           service, or five days, not including Saturdays, Sundays, or national
           holidays, after mailing if mailed by first class United States mail,
           certified or registered with return receipt requested, postage
           prepaid, and addressed as follows:

                  To Geron at:              Geron Corporation
                                            230 Constitution Drive
                                            Menlo Park, California  94025
                                            Attention: General Counsel
                                            Telephone:        (650) 473-7700
                                            Facsimile:        (650) 473-7750

                  To Transgenomic at:       Transgenomic, Inc.
                                            12325 Emmet Street
                                            Omaha, Nebraska 68164
                                            Attention:  Law Department
                                            Telephone:        (402) 452-5400
                                            Facsimile:        (402) 452-5447

    10.    BINDING EFFECT. This agreement shall be binding upon the heirs, legal
           representatives and successors of Geron and of Transgenomic;
           provided, however, that Transgenomic may not assign any rights or
           obligations under this agreement.

    11.    GOVERNING LAW. This agreement shall be governed by and construed in
           accordance with the laws of the State of California.

    12.    INVALID PROVISIONS. In the event that any provision of this agreement
           is found to be invalid or otherwise unenforceable by a court or other
           tribunal of competent jurisdiction, such invalidity or
           unenforceability shall not be construed as rendering any other
           provision contained herein invalid or unenforceable, and all such
           other provisions shall be given full force and effect to the same
           extent as though the invalid and unenforceable provision was not
           contained herein.

    13.    COUNTERPARTS. This agreement may be executed in any number of
           identical counterparts, each of which shall be deemed an original,
           but all of which together shall constitute one and the same
           instrument.

    14.    AMENDMENTS. This agreement or any provision hereof may be changed,
           waived, or terminated only by a statement in writing signed by the
           party against whom such change, waiver or termination is sought to be
           enforced.

    15.    FUTURE COOPERATION. Each of the parties hereto agrees to cooperate at
           all times from and after the date hereof with respect to all of the
           matters described herein, and to execute such further assignments,
           releases, assumptions, amendments of the agreement, notifications and
           other documents as may be reasonably requested for the purpose of
           giving effect to, or evidencing or giving notice of, the transactions
           contemplated by this agreement.

                                       7

<PAGE>

    16.    ENTIRE AGREEMENT. This agreement and the supply agreement, including
           addendum agreement no. 9 thereto, constitute the entire agreement of
           the parties pertaining to the shares and supersede all prior and
           contemporaneous agreements, representations, and understandings of
           the parties with respect thereto.

         IN WITNESS WHEREOF, the parties hereto have executed this Common Stock
Purchase Agreement as of the date first above written.

                                    Geron Corporation

                                    /s/ David L. Greenwood
                                    -------------------------------------------
                                    By: David L. Greenwood
                                    Title: Executive Vice President and Chief
                                           Financial Officer

                                    Transgenomic, Inc.

                                    /s/ Mitchell L. Murphy
                                    --------------------------------------------
                                    By: Mitchell L. Murphy
                                    Title: Vice President, Secretary & Treasurer

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]